Mutation and Transcriptional Profiling of Formalin-Fixed Paraffin Embedded Specimens as Companion Methods to Immunohistochemistry for Determining Therapeutic Targets in Oropharyngeal Squamous Cell Carcinoma (OPSCC): A Pilot of Proof of Principle

Head and Neck Pathology

Volumn 9, Issue 2, 2015, Pages 223-235

  Saba, Nabil F ^a   Wilson, Malania ^a   Doho, Gregory ^a   DaSilva, Juliana ^a   Benjamin Isett, R ^a   Newman, Scott ^a   Chen, Zhuo Georgia ^a   Magliocca, Kelly ^a   Rossi, Michael R ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer mutation profiling; Carcinoma of the oropharynx; Head and neck cancer molecular profiling; HPV related oropharynx cancer; Next generation sequensing in head and neck cancer; RNA seq in head and neck cancer

Indexed keywords

ANTINEOPLASTIC AGENT; DNA GLYCOSYLTRANSFERASE; OXOGUANINE GLYCOSYLASE 1, HUMAN; PLATELET DERIVED GROWTH FACTOR; PLATELET-DERIVED GROWTH FACTOR A; TUMOR MARKER; WNT1 PROTEIN; WNT1 PROTEIN, HUMAN;

CARCINOMA, SQUAMOUS CELL; COMPARATIVE STUDY; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN; IMMUNOHISTOCHEMISTRY; MUTATION; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PILOT STUDY; PROCEDURES; VIROLOGY;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; DNA GLYCOSYLASES; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PILOT PROJECTS; PLATELET-DERIVED GROWTH FACTOR; TRANSCRIPTION, GENETIC; WNT1 PROTEIN;

EID: 84939972637     PISSN: 1936055X     EISSN: 19360568     Source Type: Journal    
DOI: 10.1007/s12105-014-0566-0     Document Type: Article

References (60)

1. Simard EP, Torre LA, Jemal A. International trends in head and neck cancer incidence rates: differences by country, sex and anatomic site. Oral Oncol. 2014; Feb 12th.
2. D’Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007;356:1944–56.
3. Saba NF, Goodman M, Ward K, et al. Gender and ethnic disparities in incidence and survival of squamous cell carcinoma of the oral tongue, base of tongue, and tonsils: a surveillance, epidemiology and end results program-based analysis. Oncology. 2011;81:12–20.
4. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol. 2008;26:612–9.
5. Ragin CC, Taioli E. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer. 2007;121:1813–20.
6. Rampias T, Sasaki C, Weinberger P, Psyrri A. E6 and E7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells. J Natl Cancer Inst. 2009;101:412–23.
7. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24–35.
8. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008;100:261–9.
9. Lau HY, Brar S, Klimowicz AC, et al. Prognostic significance of p16 in locally advanced squamous cell carcinoma of the head and neck treated with concurrent cisplatin and radiotherapy. Head Neck. 2011;33:251–6.
10. Nichols AC, Faquin WC, Westra WH, et al. HPV-16 infection predicts treatment outcome in oropharyngeal squamous cell carcinoma. Otolaryngol Head Neck Surg. 2009;140:228–34.
11. Liang C, Marsit CJ, McClean MD, et al. Biomarkers of HPV in head and neck squamous cell carcinoma. Cancer Res. 2012;72:5004–13.
12. Holzinger D, Schmitt M, Dyckhoff G, Benner A, Pawlita M, Bosch FX. Viral RNA patterns and high viral load reliably define oropharynx carcinomas with active HPV16 involvement. Cancer Res. 2012;72:4993–5003.
13. Schlecht NF, Burk RD, Adrien L, et al. Gene expression profiles in HPV-infected head and neck cancer. J Pathol. 2007;213:283–93.
14. Sehn JK, Hagemann IS, Pfeifer JD, Cottrell CE, LockWood CM. Diagnostic utility of targeted next-generation sequencing in problematic cases. Am J Surg Pathol. 2014;38:534–41.
15. Hunt JL, Barnes L, Lewis JS, et al. Molecular diagnostic alterations in squamous cell carcinoma of the head and neck and potential diagnostic applications. Eur Arch Otorhinolaryngol. 2014;271:211–23.
16. Brunotto M, Zarate AM, Bono A, Barra JL, Berra S. Risk genes in head and neck cancer: a systematic review and meta-analysis of last 5 years. Oral Oncol. 2014;50:178–88.
17. Lewis JS Jr. p16 Immunohistochemistry as a standalone test for risk stratification in oropharyngeal squamous cell carcinoma. Head Neck Pathol. 2012;6.
18. Singh RR, Patel KP, Routbort MJ, et al. Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. J Mol Diagn. 2013;15:607–22.
19. Tsongalis GJ, Peterson JD, de Abreu FB, et al. Routine use of the ion torrent AmpliSeq cancer hotspot panel for identification of clinically actionable somatic mutations. Clin Chem Lab Med. 2014;52:707–14.
20. Jia P, Pao W, Zhao Z. Patterns and processes of somatic mutations in nine major cancers. BMC Med Genomics. 2014;7:11.
21. Do H, Dobrovic A. Dramatic reduction of sequence artefacts from DNA isolated from formalin-fixed cancer biopsies by treatment with uracil- DNA glycosylase. Oncotarget. 2012;3:546–58.
22. Forbes SA, Bindal N, Bamford S, et al. COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Res. 2011;39:D945–50.
23. Genomes Project C, Abecasis GR, Altshuler D, et al. A map of human genome variation from population-scale sequencing. Nature. 2010;467:1061–73.
24. Chen Y, McGee J, Chen X, et al. Identification of druggable cancer driver genes amplified across TCGA datasets. PLoS One. 2014;9:e98293.
25. Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401–4.
26. Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1.
27. Lui VW, Hedberg ML, Li H, et al. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov. 2013;3:761–9.
28. Pickering CR, Zhang J, Yoo SY, et al. Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov. 2013;3:770–81.
29. Pickering CR, Zhang J, Neskey DM, et al. Squamous cell carcinoma of the oral tongue in young non-smokers is genomically similar to tumors in older smokers. Clin Cancer Res. 2014;20:3842–8.
30. Pickering CR, Shah K, Ahmed S, et al. CT imaging correlates of genomic expression for oral cavity squamous cell carcinoma. AJNR Am J Neuroradiol. 2013;34:1818–22.
31. Beard RE, Abate-Daga D, Rosati SF, et al. Gene expression profiling using nanostring digital RNA counting to identify potential target antigens for melanoma immunotherapy. Clin Cancer Res. 2013;19:4941–50.
32. Laborde RR, Wang VW, Smith TM, et al. Transcriptional profiling by sequencing of oropharyngeal cancer. Mayo Clin Proc. 2012;87:226–32.
33. Nichols AC, Chan-Seng-Yue M, Yoo J, et al. A pilot study comparing HPV-positive and HPV-negative head and neck squamous cell carcinomas by whole exome sequencing. ISRN Oncol. 2012;2012:809370.
34. Zhang Y, Yuan L, Fu L, Liu C, Liu D, Mei C. Overexpression of p18INK(4)C in LLC-PK1 cells increases resistance to cisplatin-induced apoptosis. Pediatr Nephrol. 2011;26:1291–301.
35. Clark ES, Brown B, Whigham AS, Kochaishvili A, Yarbrough WG, Weaver AM. Aggressiveness of HNSCC tumors depends on expression levels of cortactin, a gene in the 11q13 amplicon. Oncogene. 2009;28:431–44.
36. Bragado P, Estrada Y, Sosa MS, et al. Analysis of marker-defined HNSCC subpopulations reveals a dynamic regulation of tumor initiating properties. PLoS One. 2012;7:e29974.
37. Singh J, Jayaraj R, Baxi S, Mileva M, Curtin J, Thomas M. An Australian retrospective study to evaluate the prognostic role of p53 and eIF4E cancer markers in patients with head and neck squamous cell carcinoma (HNSCC): study protocol. Asian Pac J Cancer Prev. 2013;14:4717–21.
38. Mahjabeen I, Chen Z, Zhou X, Kayani MA. Decreased mRNA expression levels of base excision repair (BER) pathway genes is associated with enhanced Ki-67 expression in HNSCC. Med Oncol. 2012;29:3620–5.
39. Lemaire F, Millon R, Young J, et al. Differential expression profiling of head and neck squamous cell carcinoma (HNSCC). Br J Cancer. 2003;89:1940–9.
40. Laytragoon-Lewin N, Rutqvist LE, Lewin F. DNA methylation in tumour and normal mucosal tissue of head and neck squamous cell carcinoma (HNSCC) patients: new diagnostic approaches and treatment. Med Oncol. 2013;30:654.
41. Hass HG, Schmidt A, Nehls O, Kaiser S. DNA ploidy, proliferative capacity and intratumoral heterogeneity in primary and recurrent head and neck squamous cell carcinomas (HNSCC)–potential implications for clinical management and treatment decisions. Oral Oncol. 2008;44:78–85.
42. Lui VW, Hedberg ML, Li H, et al. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov. 2013;3(7):761–9.
43. Walter V, Yin X, Wilkerson MD, et al. Molecular subtypes in head and neck cancer exhibit distinct patterns of chromosomal gain and loss of canonical cancer genes. PLoS One. 2013;8:e56823.
44. McBride SM, Rothenberg SM, Faquin WC, et al. Mutation frequency in 15 common cancer genes in high-risk head and neck squamous cell carcinoma (HNSCC). Head Neck. 2013.
45. Stransky N, Egloff AM, Tward AD, et al. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011;333(6046):1157–60.
46. Jung AC, Job S, Ledrappier S, et al. A poor prognosis subtype of HNSCC is consistently observed across methylome, transcriptome, and miRNome analysis. Clinical Cancer Res. 2013;19:4174–84.
47. Georgolios A, Batistatou A, Manolopoulos L, Charalabopoulos K. Role and expression patterns of E-cadherin in head and neck squamous cell carcinoma (HNSCC). J Exp Clin Cancer Res. 2006;25:5–14.
48. Agrawal N, Frederick MJ, Pickering CR, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science. 2011;6046.
49. Agrawal N, Frederick MJ, Pickering CR, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science. 2011;333:1154–7.
50. Gaykalova DA, Mambo E, Choudhary A, et al. Novel insight into mutational landscape of head and neck squamous cell carcinoma. PLoS One. 2014;9:e93102.
51. Stransky N, Egloff AM, Tward AD, et al. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011;333:1157–60.
52. Chiosea SI, Grandis JR, Lui VW, et al. PIK3CA, HRAS and PTEN in human papillomavirus positive oropharyngeal squamous cell carcinoma. BMC Cancer. 2013;13:602.
53. Nichols AC, Palma DA, Chow W, et al. High frequency of activating PIK3CA mutations in human papillomavirus-positive oropharyngeal cancer. JAMA Otolaryngol Head Neck Surg. 2013;139(6):617–22.
54. Wang X, Meyers C, Guo M, Zheng ZM. Upregulation of p18Ink4c expression by oncogenic HPV E6 via p53-miR-34a pathway. Int J Cancer. 2011;129:1362–72.
55. Sikka A, Kaur M, Agarwal C, Deep G, Agarwal R. Metformin suppresses growth of human head and neck squamous cell carcinoma via global inhibition of protein translation. Cell Cycle. 2012;11:1374–82.
56. Chuang JY, Huang YL, Yen WL, Chiang IP, Tsai MH, Tang CH. Syk/JNK/AP-1 signaling pathway mediates interleukin-6-promoted cell migration in oral squamous cell carcinoma. Int J Mol Sci. 2014;15:545–59.
57. Luangdilok S, Box C, Patterson L, et al. Syk tyrosine kinase is linked to cell motility and progression in squamous cell carcinomas of the head and neck. Cancer Res. 2007;67:7907–16.
58. Currie KS, Kropf JE, Lee T, et al. Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase. J Med Chem. 2014;57:3856–73.
59. Worden B, Yang XP, Lee TL, et al. Hepatocyte growth factor/scatter factor differentially regulates expression of proangiogenic factors through Egr-1 in head and neck squamous cell carcinoma. Cancer Res. 2005;65:7071–80.
60. Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;1:3021–31.